METHODS: We retrospectively analyzed the data of people living with HIV (PLWH) on antiretroviral therapy (ART) with BIC-STR followed by the Clinic of Infectious Diseases of Perugia (Perugia, Italy) from September 2019 to February 2023.
RESULTS: 270 PLWH were enrolled with a median follow-up time on BIC-STR of 2.2 years (IQR 1.2-2.7). In the overall population, in treatment-experienced (N = 242), in treatment-naïve (N = 28), and in population with age > 60 years old (N = 86), we observed that CD4 cell count improved in absolute number, percentage and CD4/CD8 ratio, under BIC-STR. Patients with viremia < 50 cp/mL increased in all groups. In the overall population, previous ART with TAF and nadir CD4 cell count favored immunological recovery. In the ART-experienced group, time in therapy with BIC-STR was associated with HIV-RNA undetectability. In the older group, previous opportunistic infection and advanced age were associated with lower CD4 count.
CONCLUSIONS: BIC-STR was demonstrated, in real-life, to be a valid option for a switch, such as initial ART.
方法:我们回顾性分析了使用BIC-STR进行抗逆转录病毒治疗(ART)的HIV感染者(PLWH)的数据,然后是佩鲁贾传染病诊所(佩鲁贾,意大利)从2019年9月到2023年2月。
结果:270PLWH入组,BIC-STR的中位随访时间为2.2年(IQR1.2-2.7)。在总人口中,在治疗经验中(N=242),在治疗初期(N=28),在年龄>60岁的人群中(N=86),我们观察到CD4细胞计数的绝对数量提高,百分比和CD4/CD8比率,根据BIC-STR。所有组病毒血症<50cp/mL的患者均增加。在总人口中,先前使用TAF和最低点CD4细胞计数的ART有利于免疫恢复。在有ART经验的小组中,BIC-STR治疗时间与HIV-RNA不可检测性相关.在老年群体中,既往机会性感染和高龄与CD4计数降低相关.
结论:证明了BIC-STR,在现实生活中,是开关的有效选项,比如最初的艺术。